Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CTNM

Contineum Therapeutics Inc

Dec 11 • 04:00PM ET

14.25

Dollar change -0.17
Percentage change -1.18	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX BIIB GILD AMGN MRNA BMY LLY PFE JNJ

| Held by: VTI IWM VXF VTWO IWO SCHA IWN IWC GSSC VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.12	Insider Own	45.42%	Shs Outstand	19.01M	Perf Week	0.85%
Market Cap	367.33M	Forward P/E	-	EPS next Y	-1.81	Insider Trans	-0.06%	Shs Float	14.07M	Perf Month	-26.32%
Income	-28.89M	PEG	-	EPS next Q	-0.43	Inst Own	39.93%	Short Float	7.38%	Perf Quarter	-21.05%
Sales	0.00M	P/S	-	EPS this Y	-4357.78%	Inst Trans	12.16%	Short Ratio	12.74	Perf Half Y	-14.47%
Book/sh	8.17	P/B	1.74	EPS next Y	5.74%	ROA	-	Short Interest	1.04M	Perf Year	-
Cash/sh	8.30	P/C	1.72	EPS next 5Y	-	ROE	-	52W Range	12.33 - 22.00	Perf YTD	-7.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-13.74%	52W High	-35.23%	Beta	-
Dividend TTM	-	Quick Ratio	37.06	Sales past 5Y	0.00%	Gross Margin	-	52W Low	15.57%	ATR (14)	0.96
Dividend Ex-Date	-	Current Ratio	37.06	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	40.51	Volatility	5.32% 7.54%
Employees	31	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.25	Target Price	29.25
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-124.69%	Payout	-	Rel Volume	0.58	Prev Close	14.42
Sales Surprise	-	EPS Surprise	2.44%	Sales Q/Q	-100.00%	Earnings	Nov 06 AMC	Avg Volume	81.45K	Price	14.25
SMA20	-5.18%	SMA50	-12.26%	SMA200	-17.57%	Trades		Volume	47,148	Change	-1.18%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-22-24	Initiated	Robert W. Baird	Outperform	$32
Apr-30-24	Initiated	Stifel	Buy	$29
Apr-30-24	Initiated	RBC Capital Mkts	Outperform	$30
Apr-30-24	Initiated	Morgan Stanley	Overweight	$25

Nov-25-24 08:05AM	Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference (Business Wire) +9.01%
Nov-18-24 08:05AM	Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain (Business Wire) -8.02%
Nov-13-24 04:05PM	Contineum Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
Nov-06-24 04:05PM	Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) +7.60%
Aug-28-24 04:05PM	Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences (Business Wire) -7.00%
04:05PM	Loading…
Aug-13-24 04:05PM	Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) -6.06% +6.21%
Jul-31-24 04:05PM	Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis (Business Wire) -5.33%
Jun-24-24 04:05PM	Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors (Business Wire)
Jun-04-24 04:05PM	Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference (Business Wire)
Jun-03-24 04:05PM	Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary (Business Wire)
May-20-24 04:05PM	Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors (Business Wire)
May-16-24 04:05PM	Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Apr-04-24 09:02PM	Contineum Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lorrain Daniel S.	Chief Scientific Officer	Nov 25 '24	Sale	16.02	1,010	16,177	168,562	Nov 27 05:06 PM
Lorrain Daniel S.	Chief Scientific Officer	Nov 18 '24	Sale	16.38	6,190	101,421	169,572	Nov 20 05:07 PM
DANIEL LORRAIN	Officer	Nov 18 '24	Proposed Sale	17.21	26,370	453,828		Nov 18 05:05 PM
Huhn Stephen L.	CMO & Sr VP, Clinical Dev.	Aug 13 '24	Option Exercise	1.01	12,800	12,928	12,800	Aug 14 06:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTNM

Contineum Therapeutics Inc

Upgrade your FINVIZ experience